Download Files:

AZD-9574

$400$3,050

Products Details

Product Description

– AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD+ breast cancer and advanced solid malignancies research[1].

Web ID

– HY-145804

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C21H22F2N6O2

References

– [1]Hybrid meeting divulges structures of drug candidates |[2]1.Kunzah Jamal, et al. Abstract 2609: AZD9574 is a novel, brain penetrant PARP-1 selective inhibitor with activity in an orthotopic, intracranial xenograft model with aberrant DNA repair. Cancer Res (2022) 82 (12_Supplement): 2609.

CAS Number

– 2756333-39-6

Molecular Weight

– 428.44

Compound Purity

– 99.11

SMILES

– O=C(C1=NC(F)=C(N2CCN(CC2)CC3=C(F)C4=C(N=C(C)C(N4)=O)C=C3)C=C1)NC

Clinical Information

– Phase 2

Research Area

– Neurological Disease

Solubility

– DMSO : 22.22 mg/mL (ultrasonic;adjust pH to 4 with HCl)|DMSO : 8.33 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– PPAR

Isoform

– PPAR

Pathway

– Cell Cycle/DNA Damage;Vitamin D Related/Nuclear Receptor

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.